The Budget provides proof of the United Progressive Alliance government having forgotten the importance of its own “flagship schemes”. BUDGET 2012-13 provides conclusive proof that the United Progressive Alliance (UPA) government has lost its way. It has managed the remarkable feat of upsetting almost everyone and making no one happy. The Budget is highly regressive in both taxation and spending terms and will raise prices of essentials, so aam aurat and...

Ashish Bose is a veteran demographer whose expertise in analysing population data persuaded the former Prime Minister, the late Rajiv Gandhi to make him an advisor on issues ranging from urbanisation to poverty alleviation. He is best known for coining the term Bimaru (shorthand for Bihar, Madhya Pradesh, Rajasthan and Uttar Pradesh) for states with the worst socio-economic indicators. An author of 24 books, he is now working on a...

One man’s fiscal problem is another man’s lifeline. Trigger happy bureaucrats and economists may love shooting down subsidies because it bloats the fiscal deficit and burdens the government but the simple fact is that in a one billion strong nation, in which nearly one in every three live below the poverty line, one needs an effective and efficient method through which privileged tax payers can support the poor. Last week, finance...

At a time when economic wisdom is seen as lying in allowing unrestrained play of economic power and cutting social sector spending, here is a report emphasising the economic sense in addressing hunger, especially child malnutrition. It also brings out the positive impact of employment guarantee scheme, which has been a thrust area of the UPA government but has seen a cut in allocation in Budget proposals for 2012-13. The report...

In a landmark decision, India’s intellectual property office on Monday allowed Hyderabad-based Natco Pharma Ltd to make and sell a copycat version of German drug maker Bayer AG’s patented cancer treatment Nexavar. It’s the first time that an Indian company has been granted the so-called compulsory licence to market a generic version of a patented drug. The drug, patented by Bayer in India in 2008, is used in the treatment of...